<DOC>
	<DOCNO>NCT02966093</DOCNO>
	<brief_summary>The primary purpose study compare progression-free survival ( PFS ) participant radioiodine ( 131 I ) -refractory differentiate thyroid cancer ( DTC ) radiographic evidence disease progression within prior 12 month treat lenvatinib 24 mg continuous daily ( QD ) oral dose versus placebo .</brief_summary>
	<brief_title>A Trial Lenvatinib ( E7080 ) Radioiodine ( 131 I ) -Refractory Differentiated Thyroid Cancer China</brief_title>
	<detailed_description>This study conduct 3 phase : Prerandomization Phase , Randomization Phase , Extension Phase . The Extension Phase consist Optional Open Label ( OOL ) Lenvatinib Treatment Period Follow-up Period .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion criterion : 1 . Participants must histologically cytologically confirm diagnosis one following Differentiated Thyroid Cancer ( DTC ) subtypes : a. Papillary thyroid cancer ( PTC ) i. Follicular variant ii . Variants ( include limit tall cell , columnar cell , cribriformmorular , solid , oxyphil , Warthin'slike , trabecular , tumor nodular fasciitislike stroma , Hürthle cell variant papillary carcinoma , poorly differentiate ) b. Follicular thyroid cancer ( FTC ) i. Hürthle cell ii . Clear cell iii . Insular 2 . Measurable disease meeting follow criterion confirm central radiographic review : 1 . At least 1 lesion ≥ 1.0 centimeter ( cm ) long diameter non lymph node ≥ 1.5 cm shortaxis diameter lymph node serially measurable accord Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 use computerize tomography/magnetic resonance imaging ( CT/MRI ) . If one target lesion nonlymph node , long diameter ≥ 1.5 cm . 2 . Lesions external beam radiotherapy ( EBRT ) locoregional therapy radiofrequency ( RF ) ablation must show evidence progressive disease ( substantial size increase ≥ 20 % ) deem target lesion . 3 . Participants must show evidence disease progression comparing ( ) scan screen ( b ) historical scan obtain within 12 month prior sign inform consent , accord RECIST 1.1 assess confirmed central radiographic review CT and/or MRI scan . 4 . Participants must eligible possible curative surgery must radioiodine ( 131 I ) refractory / resistant define least one following : 1 . One measurable lesion demonstrate iodine uptake radioiodine scan 2 . One measurable lesion progress RECIST 1.1 within 12 month 131 I therapy , despite demonstration radioiodine avidity time treatment pre posttreatment scan . 3 . Cumulative activity 131 I &gt; 600 millicurie ( mCi ) 22 gigabecquerels ( GBq ) , last dose administer least 6 month prior study entry 5 . Participants may receive 0 1 prior vascular endothelial growth factor/ vascular endothelial growth factor receptor ( VEGF/VEGFR ) target therapy ( example sorafenib , sunitinib , pazopanib , etc. ) . Each VEGF/VEGFR target agent count individually , regardless duration administration . 6 . Participants know brain metastasis complete whole brain radiotherapy , stereotactic radiosurgery complete surgical resection , eligible remain clinically stable , asymptomatic steroid one month . 7 . Participants must receive thyroxine suppression therapy thyroid stimulate hormone ( TSH ) elevate ( TSH ≤ 0.1 milliunits/Liter [ mU/L ] ) . 8 . All chemotherapy radiation related toxicity must resolve &lt; Grade 2 severity per Common Terminology Criteria Adverse Events ( CTCAE v 4.0 ) , except alopecia infertility . 9 . Participants must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 . 10 . Adequately control blood pressure ( BP ) without antihypertensive medication , define BP ≤ 150/90 millimeter mercury ( mm Hg ) screen change antihypertensive medication within 1 week prior Cycle 1/Day 1 11 . Adequate renal function define calculated creatinine clearance ≥ 30 mL/min per Cockcroft Gault formula 12 . Adequate bone marrow function : 1 . Absolute neutrophil count ( ANC ) ≥ 1500 per cubic meter ( mm3 ) ( ≥ 1.5 × 103/micro liter [ μL ] ) 2 . Platelets ≥ 100,000/mm3 ( ≥ 100 × 10^9/ liter [ L ] ) 3 . Hemoglobin ≥ 9.0 gram per deciliter ( g/dL ) 13 . Adequate blood coagulation function evidence International Normalized Ratio ( INR ) ≤ 1.5 14 . Adequate liver function : 1 . Bilirubin ≤ 1.5 × upper limit normal ( ULN ) except unconjugated hyperbilirubinemia Gilbert 's syndrome 2 . Alkaline phosphatase , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ≤ 3 × ULN ( ≤ 5 × ULN participant liver metastasis ) . 15 . Males females age ≥ 18 year time inform consent 16 . Females must lactate pregnant Screening Baseline ( document negative human chorionic gonadotropin [ hCG ] test minimum sensitivity 25 international unit per liter ( IU/L ) equivalent unit hCG ) . A separate baseline assessment require negative screening pregnancy test obtain 72 hour first dose study drug . 17 . All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group , without know suspected cause ) sterilize surgically ( ie , bilateral tubal ligation , total hysterectomy , bilateral oophorectomy , surgery least 1 month dose ) . 18 . Females childbearing potential must unprotected sexual intercourse within 30 day prior study entry must agree use highly effective method contraception ( e.g. , total abstinence , intrauterine device , doublebarrier method [ condom plus diaphragm spermicide ] , contraceptive implant , oral contraceptive , vasectomized partner confirm azoospermia ) throughout entire study period 30 day study drug discontinuation . If currently abstinent , participant must agree use doublebarrier method describe becomes sexually active study period 30 day study drug discontinuation . Females use hormonal contraceptive must stable dose hormonal contraceptive product least 4 week prior dose must continue use contraceptive study 30 day study drug discontinuation . 19 . Male participant must successful vasectomy ( confirm azoospermia ) female partner must meet criterion ( ie , childbearing potential practicing highly effective contraception throughout study period 30 day study drug discontinuation ) . Those partner use hormonal contraceptive must also use additional approve method contraception , describe previously . 20 . Voluntary agreement provide write informed consent willingness ability comply aspects protocol Exclusion criterion : 1 . Anaplastic medullary carcinoma thyroid 2 . Two prior VEGF/VEGFRtargeted therapy ongoing treatment 131 Irefractory DTC TSHsuppressive thyroid hormone therapy 3 . Prior treatment lenvatinib 4 . Participants receive anticancer treatment ( include Chinese herbal medicine specify treatment tumor ) within 21 day investigational agent within 30 day prior first dose study drug . This apply use TSHsuppressive thyroid hormone therapy . 5 . Major surgery within 3 week prior first dose study drug 6 . Participants &gt; 1 + proteinuria urine dipstick testing ( Participants urine protein &lt; 1 g/24 hour ( h ) eligible ) . 7 . Gastrointestinal malabsorption condition opinion investigator might affect absorption lenvatinib 8 . Significant cardiovascular impairment : history ( ) congestive heart failure great New York Heart association ( NYHA ) Class II , ( b ) unstable angina , ( c ) myocardial infarction , ( ) stroke , ( e ) cardiac arrhythmia associate impairment within 6 month first dose study drug 9 . Prolongation correct Q wave T wave ( QTc ) interval &gt; 480 millisecond ( m ) 10 . Bleeding thrombotic disorder ( Treatment low molecular weight heparin [ LMWH ] allow . ) 11 . Radiographic evidence major blood vessel invasion/infiltration 12 . Active hemoptysis ( bright red blood least 0.5 teaspoon ) within 3 week prior first dose study drug 13 . Active infection ( infection require systemic treatment ) 14 . Active malignancy ( except DTC definitively treat basal squamous cell carcinoma skin , carcinoma insitu cervix bladder ) within past 24 month 15 . Known intolerance study drug ( excipients ) 16 . Any medical condition , opinion investigator , would preclude participation clinical trial 17 . Females pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Differentiated thyroid cancer</keyword>
	<keyword>Chinese participant</keyword>
	<keyword>Phase 3</keyword>
	<keyword>Lenvatinib</keyword>
	<keyword>E7080</keyword>
</DOC>